Conclusion: Cisplatin plus etoposide chemotherapy for recurrent / metastatic stages in large cell neuroendocrine lung carcinoma had a improvement survival outcome with a median of 12 ±1, 354 months, and the number of metastatic organs and performance status were two factors affected survival outcome.